Treatment of post-acne erythema with a 589 nm Solid-state Laser Versus placebo cream in Asians: A Split Face, Single-blinded, Randomized Controlled Trial
Phase 3
- Conditions
- The healthy patient between 18 to 50 years old who have no active acne or mild to moderate bilateral facial inflammatory acne with bilateral post-acne erythemaPost acne erythema
- Registration Number
- TCTR20230217005
- Lead Sponsor
- Division of Dermatology, Department of Internal Medicine,Faculty of Medicine, Ramathibodi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1. Healthy males and females between 18 to 50 years old
2. Patients who have no active acne or mild to moderate bilateral facial
inflammatory acne with bilateral post-acne erythema
3. Fitzpatrick skin Types III to V
Exclusion Criteria
1. Pregnant or lactating woman
2. Patients who had received oral vitamin A derivatives in the past 3 months
3. Patients receiving facial laser treatments within the past 1 months
4. Patients with history of photosensitive disease
5.Patients with any medical condition that might affect acne and wound healing process
6.Patients with skin infection or history of skin cancer
7.Patients who withdrew from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compare improvement of post-acne erythema between solid state 589 nm laser versus placebo cream (aloe vera) in the treatment of post-acne erythema at 2,4,6,8,10,12,14,18 weeks after the begin of intervention Investigator global assessment scale, Visit camera, Antera 3D skin analysis, 10 point clinical assessment score
- Secondary Outcome Measures
Name Time Method 1.patient satisfaction after treatment post acne erythema between solid state 589 nm laser versus placebo cream(aloe vera) 2.side effect from solid state 589nm laser patient record side effect at 0,2,4,6,8,10,12,14,18 weeks and pain score assessment at 0,2,4,6,8,10 weeks and patient satisfaction score at 10,12,14,18 weeks after the begin of intervention patient record side effect ,10 point pain score assessment , 10 point patient satisfaction score